We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Northwest Biotherapeutics announced that the first two patients in its pivotal Phase II clinical trial have undergone surgery for newly diagnosed glioblastoma multiforme (GBM), which is the first step in the preparation of the company's DCVax-Brain treatment.
Dynogen Pharmaceuticals has reported positive results from its randomized, double-blind, placebo-controlled, parallel-group, Phase II trial of DDP733 in patients with irritable bowel syndrome (IBS) with constipation.
Kamada has submitted plans to the European Medicines Agency (EMEA) for its Phase II/III trial of an aerosolized formulation of Alpha-1 Antitrypsin (AAT).
Neurochem has received a second recommendation from a data safety monitoring board (DSMB) to continue its ongoing European Phase III clinical trial for Alzhemed (tramiprosate), the company's investigational product candidate for the treatment of Alzheimer's disease.
Emergent BioSolutions announced that the FDA has granted fast-track designation to its BioThrax anthrax vaccine as a post-exposure prophylaxis against anthrax infection.
Seattle Genetics announced that FDA has granted orphan drug designation to SGN-33 for the treatment of acute myeloid leukemia (AML) and to SGN-35 for the treatment of Hodgkin's disease.